A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Active:	Yes
Cancer Type:	Colon/Rectal Cancer	NCT ID:	NCT07114601
Trial Phases:	Phase I	Protocol IDs:	27354 (primary) NCI-2025-06835 2025-522367-15-00 J6C-OX-JKFA
Eligibility:	18 Years and older, Male and Female	Study Type:	Basic Science
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT07114601

Summary

The main purpose of this study is to evaluate safety, tolerability, and efficacy of
LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in
participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast,
colorectal, prostate, and endometrial cancer. The study will also evaluate the safety,
tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein
called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until
your tumor progresses.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.